Contents lists available at ScienceDirect





journal homepage: www.elsevier.com/locate/bmcl

Synthesis and SAR of novel, non-MPEP chemotype mGluR5 NAMs identified by functional HTS

Ya Zhou^{a,c,†}, Alice L. Rodriguez^{a,c,†}, Richard Williams^{a,c}, C. David Weaver^{a,c}, P. Jeffrey Conn^{a,c}, Craig W. Lindsley^{a,b,c,*}

^a Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
^b Department of Chemistry, Vanderbilt University, Nashville, TN 37232, USA

^c Vanderbilt Program in Drug Discovery, Nashville, TN 37232, USA

ARTICLE INFO

Article history: Received 21 July 2009 Revised 12 October 2009 Accepted 14 October 2009 Available online 28 October 2009

Keywords: mGluR5 Negative allosteric modulator Positive allosteric modulator

ABSTRACT

This Letter describes the discovery and SAR of three novel series of mGluR5 non-competitive antagonists/ negative allosteric modulators (NAMs) not based on manipulation of an MPEP/MTEP chemotype identified by a functional HTS approach. This work demonstrates fundamentally new mGluR5 NAM chemotypes with submicromolar potencies, and further examples of a mode of pharmacology 'switch' to provide PAMs with a non-MPEP scaffold.

© 2009 Elsevier Ltd. All rights reserved.

Metabotropic glutamate receptors (mGluRs) are members of the G protein-coupled receptor (GPCR) family C, which is distinguished from other GPCR families by its large extracellular N-terminal agonist binding site. There are eight subtypes of mGluRs (Group I: mGluR1 and mGluR5; Group II: mGluR2 and mGluR3; Group III: mGluRs 4, 6, 7, 8) based on their sequence homology, pharmacology and coupling to effector mechanisms.¹ The mGluRs bind glutamate to modulate neurotransmitter release or postsynaptic excitatory neurotransmission, hence they modulate the strength of synaptic transmissions. Different from ionotropic glutamate receptors which mediate the fast excitatory neurotransmissions, metabotropic glutamate receptors play a more modulatory role and have been proposed as alternative targets for pharmacological interventions.¹

Group I receptor mGluR5 has been implicated in a number of physiological processes in the central nervous system (CNS). The discovery of highly selective mGluR5 receptor antagonists MPEP (1) and MTEP (2) was a major breakthrough (Fig. 1). MPEP (1) and MTEP (2) in preclinical models demonstrated that selective antagonism of mGluR5 has therapeutic potential for the treatment of pain, anxiety, depression, cocaine addiction and Fragile X Syndrome (FXS).²

A majority of reported non-competitive mGluR5 antagonists have employed the MPEP (1) and MTEP(2) chemotypes as a basis for ligand design.³⁻¹¹ Only a few more diverse structures, such as

thiopyrimidine (**3**) and fenobam (**4**), have been disclosed.^{12,13} Recently our group reported three novel non-MPEP chemotypes of mGluR5 antagonists (**5**, **6**, and **7**), which exemplified a dramatic departure from the MPEP scaffold.¹⁴

As a continuing effort to design and synthesize novel non-MPEP-based mGluR5 negative allosteric modulators (NAMs), in this Letter, we describe the discovery and SAR of three novel mGluR5 NAM series represented by **8**, **9** and **10** (Fig. 2). These novel leads were identified from a functional high-throughput mGluR5



Figure 1. Reported mGluR5 non-competitive antagonists/negative allosteric modulators (NAMs).

^{*} Corresponding author. Tel.: +1 615 322 8700; fax: +1 615 343 6532.

E-mail address: carig.lindsley@vanderbilt.edu (C.W. Lindsley).

[†] These authors contributed equally to this work.

⁰⁹⁶⁰⁻⁸⁹⁴X/\$ - see front matter \odot 2009 Elsevier Ltd. All rights reserved. doi:10.1016/j.bmcl.2009.10.059



Figure 2. Novel non-MPEP mGluR5 non-competitive antagonists 8, 9 and 10 identified from a functional HTS campaign.

antagonist screen of over 160,000 compounds (624 mGluR5 antagonists identified, 0.39% hit rate in the primary screen).¹⁴ Leads **8**, **9** and **10** all possess submicromolar IC_{50} s from the HTS DMSO stock solutions, good clogP values and low molecular weights, which are ideal properties for further SAR development.

Lead **8**, an *N*,*N*'-(1,3-phenylene)dibenzamide, was first investigated and SAR explored through the synthesis of two small 24-membered libraries.¹⁵ The first library aimed at holding the 2-methoxybenzamide moiety constant, while varying the other amide portion of the molecule. As illustrated in Scheme 1, synthesis of key intermediate **13** was achieved by coupling of 3-nitroaniline **11** and 2-methoxybenzoyl chloride under mild basic conditions to provide **12**, followed by hydrogenation with Raney nickel to deliver **13**. We applied an iterative parallel synthesis strategy for this library preparation, as well as all the other libraries in this letter, and resynthesized **8** in the context of a 24-member library through standard acylation of **13** with 24 commercial acid chlorides. Excess reagents were scavenged by PS-isocyanate and PS-trisamine, and the final products were purified by mass-directed preparative LC–MS to >98% purity.¹⁶

Upon resynthesis, lead **8** suffered a threefold loss in potency $(IC_{50} = 880 \text{ nM})$ compared to the HTS stock solution $(IC_{50} = 301 \text{ nM})$; however, clear SAR was still noted for this series (Table 1). Lead **8** was the most potent compound. Aromatic groups were the only active analogs; *meta*-substitution was favored (**14e**, **14g**, **14h** and **14i**, potency Cl > Me > CN > F > CF₃), any other substitution patterns in the aromatic ring were not tolerated (**14a**-**14d**, **14f** and **14j**). Introduction of other groups, such as heterocyclic derivative (**14k**), benzyl variant (**14l**), cyclic alkyl moieties (**14n**-**14r**), or acyclic alkyl derivatives (**14s**-**14u**), were all proven inactive.

A second library was prepared in similar fashion with the goal of holding the 3-chloro group constant, while changing the other amide moiety. As shown in Scheme 2, synthesis of key intermediate **16** was achieved by coupling of 3-nitroaniline **11** and 3-chorobenzoyl chloride under mild basic conditions to provide **15**. A subsequent Raney nickel-catalyzed hydrogenation at atmospheric pressure delivers **16**. A 24-member library **17** was synthesized through standard acylation of **16** with 24 readily available acid chlorides.¹⁴ Excess reagents were scavenged by PS-isocyanate



Scheme 1. Reagents and conditions: (a) 2-methoxybenzoyl chloride, DIEA, DMAP, DMF, 64%; (b) Raney nickel, H₂ (50 psi), EtOH/EtOAc (3:2), 94%; (c) (i) RCOCl, PS-DMAP, PS-DIEA; (ii)PS-isocyanate, PS-trisamine, 25–90%.

Table 1 Structures and activities of analogs 14



(continued on next page)

Table 1 (continued)

Compd	R	mGluR5 ^a IC ₅₀ (μ M)	% Glu max
14p		>30	ND
14q	125 J	>30	ND
14r	rr ^r	>30	ND
14s	د ^ج ∕ Me Me	>30	ND
14t	^{دي} Me	>30	ND
14u	ج ⁵ OMe	>30	ND

^a IC_{50s} are average of three determinations. ND not determined.

and PS-trisamine, and the final products were purified by mass-directed preparative LCMS with purity >98%.¹⁶

Generally (Table 2), aromatic groups were not well tolerated (17b-17i), with exception of the 2-chlorophenyl analog 17a $(IC_{50} = 2.62 \mu M)$ which proved to be the most potent NAM in this series, along with the cylcopropyl amide **17q**. Benzyl analog **17k**, phenylcyclopropane derivative 17l and adamantyl compound 17m proved inactive. Interestingly, 6- and 5-member cyclic alkyl moieties were inactive (17n and 17o). However, a cyclobutyl amide provided a NAM of modest potency (**17p**, $IC_{50} = 5.27 \mu M$), and further contraction to the cyclopropyl derivative 17q led to improved inhibition (IC₅₀ = 2.23 μ M). Acyclic alkyl analogs **17r** and 17s both demonstrated weak inhibition, while the ether variant 17t showed no activity. Most surprising from this library (Fig. 3) was the identification of two weak, but unexpected mGluR5 positive allosteric modulators (PAMs) 17u (EC₅₀ = 1.87 μ M, 49% Glu Max) and 17v (EC₅₀ = 5.54 μ M, 56% Glu Max), both regiosiomeric pyridine amide analogs.^{14,17,18} While weak, **17u** and **17v** represent a fundamentally new mGluR5 PAM chemotype, worthy of further optimization.17-22

From this *N*,*N*'-(1,3-phenylene)dibenzamide series, **8** was further evaluated and found to displace [³H]3-methoxy-5-(2-pyridinylethynyl) pyridine, a radioligand for the MPEP allosteric binding site on mGluR5, with a K_i value of 1.1 μ M, comparable to the IC₅₀ value (880 nM). Thus **8** represents a new mGluR5 non-competitive antagonist chemotype, inhibiting mGluR5 function by interaction with MPEP allosteric binding site. Future libraries will focus on SAR studies of the central phenyl core modifications.

Our attention was then directed to lead **9**, 3-(phthalimidyl)-*N*-(2-hydroxyphenyl)benzamide. Lead **9** possesses very similar structure to **CPPHA**,^{20,21} the only known mGluR5 allosteric ligand, a PAM, that binds at an allosteric site distinct from the MPEP-binding



Scheme 2. Reagents and conditions: (a) 3-chlorobenzoyl chloride, DIEA, DMAP, DMF, 89%; (b) Raney nickel, H₂ (1.0 atm), EtOH/EtOAc (3:2), 89%; (c) (i) RCOCl, PS-DMAP, PS-DIEA; (ii)PS-isocyanate, PS-trisamine, 28–92%.

Table 2

Structures and activities of analogs 17



^a IC_{50s} are average of three determinations.ND not determined.

site (Fig. 4). We resynthesized **9** in the context of a 22-member library. Preparation of the library was straightforward as indicated in Scheme 3. Condensation between readily available methyl 3-aminobenzoate **18** and phthalic anhydride **19** in acetic acid afforded methyl 3-(*N*-phthalimidyl)benzoate **20**. Saponification of **20** using lithium hydroxide gave benzoic acid **21**. Scaffold **21** was then coupled to 22 different amines employing HOBt/EDC, to deliver the 3-(*N*-phthalimidyl) benzamide library **22**. The final products were purified by mass-directed preparative LC–MS to >98% purity.¹⁶

Upon resynthesis, lead **9** suffered a fivefold loss in potency $(IC_{50} = 417 \text{ nM})$ compared to the HTS stock solution $(IC_{50} = 77 \text{ nM})$ (Table 3). The discrepancies between the resynthesized compounds and HTS DMSO stocks have been noted many times in our various programs previously.^{14,17} Lead **9** was still the most potent compound in this series. In general, functionalized aromatic and heteroaromatic analogs were more active (**9**, **22a–22h**), and alkyl derivatives were inactive (**22i**, **22j**, $IC_{50} > 30 \mu$ M). Moving the hydroxyl group of **9** from the 2-position to 3-position (**22a**), led to a 19-fold loss in potency ($IC_{50} = 7.79 \mu$ M). 3,5-Dimethoxyl substrate **22b** showed moderate inhibitory activity ($IC_{50} = 3.58 \mu$ M), while 2-methoxyl analog **22c** lost all the activity.



Figure 3. Novel non-MPEP mGluR5 PAMs 17u and 17v.



Figure 4. Structural similarity of 9 and non-MPEP-binding mGluR5 PAM, CPPHA.





Table 3

Structures and activities of analog 22



Compd	R	mGluR5ª IC_{50} (μM)	% Glu max
9	OH S	0.42	1.59
22a	Store OH	7.79	48.1
22b	S OMe	3.58	76.2
22c	OMe	>30	86
22d	S CI	1.78	26.4
22e	²⁵ N	>30	86
22f	S N	1.26	59.5
22g	F	1.05	49.9
22h	S F	>30	73
22i	2 ⁵	>30	68
22j	2 - Z	>30	71

^a IC_{50s} are average of three determinations.

3-Chloro derivative **22d** displayed improved potency $(IC_{50} = 1.78 \ \mu\text{M})$ compared to 3-hydroxyl analog **22a**. 3-Pyridyl compound **22e** proved inactive, however, its 2-pyridyl congener **22f** showed reasonable activity $(IC_{50} = 1.26 \ \mu\text{M})$ as a partial antagonist.²³ 2-Flouro derivative **22g** was favored over 4-flouro analog **22h**, giving good potency $(IC_{50} = 1.05 \ \mu\text{M})$ as a partial antagonist as well.²⁴ Considering the structural similarity of this series with



Figure 5. Non-MPEP chemotype NAMs 23 and 25 as well as PAM 24, a non-MPEP site ligand, from a library of analogs of 10.

the non-MPEP-binding PAM CPPHA,^{20,21} we were hoping that this series would also interact with this distinct allosteric binding site and provide the first NAM tools to study the CPPHA binding site. However, further evaluation of **9** showed the displacement of $[^{3}H]_{3}$ -methoxy-5-(2-pyridinylethynyl) pyridine with a K_{i} of 319 nM—a value comparable to the IC₅₀ (420 nM), which indicated its interaction with MPEP-binding site. Our continuing efforts will focus on modifications of both the phthalimide moiety and the central phenyl ring of the scaffold.

Lastly, our attention was directed at lead optimization of **10**, *N*-(3-(1H-benzo[d]imidazol-2-yl)-4-chlorophenyl)-5-bromofuran-2carboxamide. Once again, we resynthesized **10** in the context of a small library of analogs.¹⁵ Surprisingly, upon resynthesis, lead **10** was totally inactive (IC $_{50}$ >30 $\mu M)$ and the majority of analogs displayed only poor activity at best (IC₅₀s 10–30 µM). This effort produced three interesting compounds (Fig. 5) 23 wherein the chlorine of the central phenyl ring was replaced with hydrogen. 24 and 25 where the benzimidazole is replaced with a benzoxazole. In these examples, **23** was a weak mGluR5 NAM (IC₅₀ = 3.5μ M, 34% Glu Max), **25** was a full mGluR5 NAM (IC₅₀ = 2.1 μ M, 2.3% Glu Max) while **24** was a modestly potent mGluR5 PAM (EC₅₀ = 2.2 μ M, 68% Glu Max)-a very interesting 'switch' in the mode of mGluR5 pharmacology.^{17,18} Unlike **8** and **9**, which afforded comparable $IC_{50}s/K_{i}s$, **24** displaced [³H]3-methoxy-5-(2-pyridinylethynyl)pyridine with a K_i >10-fold less than the EC₅₀. These data are consistent with the hypothesis that the PAM activity of 24 is mediated by interaction with the MPEP site.^{25,26} Previous studies suggest that mGluR5 PAMs acting at this site display strong cooperativity with orthosteric agonists so that the mGluR5 PAM potencies are significantly greater than their affinities. However, based on these data, it is also possible that 24 does not act solely through interaction with the MPEP site, but potentially at the CPPHA site or a potentially third allosteric site on mGluR5. Studies are underway to address this question. Importantly, 8, 9, 23, 24 and 25 were selective versus mGluRs 1, 2, 3, 4, 7 and 8.

In summary, our HTS campaign identified several novel noncompetitive mGluR5 antagonists based on 8 and 9 with little or no structural and topological similarity to MPEP. An iterative parallel library synthesis strategy helped to rapidly develop SAR for these series. IC₅₀s of analogs of 8 and 9 ranged from 420 nM to 880 nM for the most potent mGluR5 NAMs and, despite divergence from the MPEP chemotype, binding experiments indicated these NAMs bound to the MPEP site. Optimization efforts also identified fundamentally new mGluR5 PAM chemotypes, represented by 17u and 17v, as well as new mGluR5 partial antagonists 22f and 22g. While lead 10 was inactive upon resynthesis, both NAMs 23 and 25 and PAM 24 were identified within an analog library, and PAM 24 displayed only weak displacement of [³H]3-methoxy-5-(2-pyridinylethynyl) pyridine, suggesting 24 may not act solely through interaction with the MPEP site. These data further highlight the complexities and subtle modifications that can alter modes of mGluR5 pharmacology for MPEP site ligands. Further refinements in this arena are in progress and will be reported in due course.

Acknowledgments

The authors thank NIDA (DA023947-01) and Seaside Therapeutics (VUMC33842) for support of our programs in the development of mGluR5 non-competitive antagonists and partial antagonists.

References and notes

 a Schoepp, D. D.; Jane, D. E.; Monn, J. A. Neuropharmacology **1999**, 38, 1431; (b) Conn, P. J.; Pin, J.-P. Annu. Rev. Pharmacol. Toxicol. **1997**, 37, 205.

- (a) Gasparini, F.; Lingenhohl, K.; Stoehr, N.; Flor, P. J.; Heinrich, M.; Vranesic, I. Neuropharmacology **1999**, 38, 1493; (b) Lea, P. M., IV; Faden, A. I. CNS Drug Rev. **2006**, *12*(2), 149.
- 3. Alagille, D.; Baldwin, R. M.; Roth, B. L.; Wroblewski, J. T.; Grajkowska, E.; Tamagnan, G. D. Bioorg. Med. Chem. Lett. **2005**, *15*, 945.
- Roppe, J. R.; Wang, B.; Huang, D.; Tehrani, L.; Kamenecka, T.; Schweiger, E. J.; Anderson, J. J.; Brodkin, J.; Jiang, X.; Cramer, M.; Chung, J.; Reyes-Manalo, G.; Munoz, B.; Cosford, N. D. P. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 3993.
- 5. Newman, A. H.; Kulkarni, S. S. Bioorg. Med. Chem. Lett. 2007, 17, 2987.
- Galatis, P.; Yamagata, K.; Wendt, J. A.; Connolly, C. J.; Mickelson, J. W.; Milbank, J. B. J.; Bove, S. E.; Knauer, C. S.; Brooker, R. M.; Augelli-Szafran, C. E.; Schwartz, R. D.; Kinsora, J. J.; Kilgore, K. S. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 6525.
- 7. Newman, A. H.; Kulkarni, S. S. Bioorg. Med. Chem. Lett. 2007, 17, 2074.
- Eastman, B.; Chen, C.; Smith, N. D.; Poon, S.; Chung, J.; Reyes-Manalo, G.; Cosford, N. D. P.; Munoz, B. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 5485.
 Bach, P.; Nilsson, K.; Svensson, T.; Baur, U.; Hammerland, L. G.; Peterson, A.;
- Wallberg, A.; Osterland, K.; Karis, D.; Boije, M.; Wensbo, D. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 4788.
- Micheli, F.; Bertani, B.; Bozzoli, A.; Crippa, L.; Cavanni, P.; Fabio, R. D.; Donati, D.; Marzorati, P.; Merlo, G.; Paio, A.; Pergunni, L.; Zarantonello, P. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 1804.
- Kulkarni, S. S.; Zhao, M.-F.; Cao, J.; Deschamps, J. R.; Rodriguez, A. L.; Conn, P. J.; Newman, A. H. J. Med. Chem. 2009, 52, 3563.
- Hammerland, L. G.; Johansson, M.; Mattson, J. P.; Minidis, A. B. E.; Nilsson, K.; Peterson, A.; Wensbo, D.; Wallberg, A.; Osterlund, K. *Bioorg. Med. Chem. Lett.* 2006, 16, 2467.
- Porter, R. H. P.; Jaeschke, G.; Spooren, W.; Ballard, T. M.; Buttelmann, B.; Kolczewski, S.; Peters, J.-U.; Prinseen, E.; Wichmann, J.; Vieira, E.; Muhlemann, A.; Gatti, S.; Mutel, V.; Malherbe, P. J. Pharmacol. Exp. Ther. 2005, 315, 711.
- (a) Rodriguez, A.L.; Williams, R.; Zhou, Y.; Lindsley, S.R.; Le, U.; Grier, M.D.; Weaver, C.D.; Conn, P.J.; Lindsley, C.W. Bioorg. Med. Chem. Lett. 2009, 19, 3209; (b) mGluR5 in vitro functional assay. HEK293A cells expressing rat mGluR5 receptor were plated (BD Falcon Poly-D-lysine Cellware) at 50,000 cells/well in assay media (DMEM, 20 mM HEPES, 10% dialyzed FBS, and 1 mM sodium pyruvate). The plates were incubated overnight at 37 °C in 5% CO₂. Media was removed and assay buffer (Hanks Balanced Salt Solution, 20 mM HEPES, 2.5 mM Probenecid, pH 7.4) containing 4.0 µM Fluo4-AM dye (Invitrogen) was added. Cells were incubated for 45 min (37 °C, 5% CO₂) to allow for dye loading. Dye was removed, 20 µL assay buffer was added and the cell plate was allowed to incubate for 10 min. After incubation in assay buffer, cell plates were loaded into Flexstation II (Molecular Devices Corp). Test compound in assay buffer was added 19 seconds into the assay and subsequently, asubmaximal (250 nM) or nearly maximal (1.25 µM) amount of glutamate was added 109 s into the assay for potentiators and antagonists, respectively. Controls included compound submaximal or nearly maximal concentrations of glutamate. Compounds submaximal or nearly maximal concentrations of glutamate. Compounds were tested in concentrations ranging from 46 pM to 100 µM. Fold shifts were determined using the same functional assay by varying the amount of glutamate in the presence of either a fixed concentration of compound (10 µM) or vehicle. A concentration response curve was generated using glutamate concentrations ranging from 4.6 nM to 10 µM. Controls included compound vehicle (0.2% DMSO) plus assay buffer, EC_{max} (100 μ M glutamate), and glutamate concentration response curve. Assays were performed in triplicate on three different days. Concentration response curves were generated using GraphPad Prism 4.0.
- Kennedy, J. P.; Williams, L.; Bridges, T. M.; Daniels, R. N.; Weaver, D.; Lindsley, C. J. Comb. Chem. 2008, 10, 345.
- 16. Leister, W. H.; Strauss, K. A.; Wisnoski, D. D.; Zhao, Z.; Lindsley, C. W. J. Comb. Chem. **2003**, *5*, 322.
- Sharma, S.; Rodriguez, A.; Conn, P. J.; Lindsley, C. W. Bioorg. Med. Chem. Lett. 2008, 18, 4098.
- Sharma, S.; Heiman, J. U.; Rook, J. M.; Jones, C. K.; Conn, P. J.; Lindsley, C. W. J. Med. Chem. 2009, 52, 4103.
- O'Brien, J. A.; Lemaire, W.; Chen, T.-B.; Chang, R. S. L.; Jacobson, M. A.; Ha, S. N.; Lindsley, C. W.; Sur, C.; Pettibone, D. J.; Conn, J.; Wiliams, D. L. *Mol. Pharmacol.* 2003, 64(3), 731.
- O'Brien, J. A.; Lemaire, W.; Wittmann, M.; Jacobson, M. A.; Ha, S. N.; Wisnoski, D. D.; Lindsley, C. W.; Schaffhauser, H. J.; Sur, C.; Duggan, M. E.; Pettibone, D. J.; Conn, J.; Williams, D. L. J. Pharmacol. Exp. Ther. 2004, 309(2), 568.
- Zhao, Z.; Wisnoski, D. D.; O'Brien, J. A.; Lemiare, W.; Williams, D. L., Jr.; Jacobson, M. A.; Wittman, M.; Ha, S.; Schaffhauser, H.; Sur, C.; Pettibone, D. J.; Duggan, M. E.; Conn, P. J.; Hartman, G. D.; Lindsley, C. W. *Bioorg. Med. Chem. Lett.* 2007, 17, 1386.
- Lindsley, C. W.; Wisnoski, D. D.; Leister, W. H.; O'Brien, J. A.; Lemiare, W.; Williams, D. L., Jr.; Burno, M.; Sur, C.; Kinney, G. G.; Pettibone, D. J.; Tiller, P. R.; Smith, S.; Duggan, M. E.; Hartman, G. D.; Conn, P. J.; Huff, J. R. J. Med. Chem. 2004, 47, 5825.
- Engers, D. W.; Rodriguez, A. L.; Oluwatola, O.; Hammond, A. S.; Venable, D. F.; Williams, R.; Sulikowski, G. A.; Conn, P. J.; Lindsley, C. W. *ChemMedChem* 2009, 4, 505.
- Rodriguez, A. L.; Nong, Yi.; Sekaran, N. K.; Alagille, D.; Tamagnan, G. D.; Conn, P. J. Mol. Pharmacol. 2005, 68, 793.
- de Paulis, T.; Hemstapat, K.; Chen, Y.; Zhang, Y.; Saleh, S.; Alagille, D.; Baldwin, R. M.; Tamagnan, G. D.; Conn, P. J. *J. Med. Chem.* **2006**, *49*, 3332.
- 26. Chen, Y.; Goudet, C.; Pin, J. P.; Conn, P. J. Mol. Pharmacol. 2008, 73, 909.